Tumor Biology

, Volume 37, Issue 1, pp 1131–1140 | Cite as

Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases

  • Arife Ulas
  • Ahmet Bilici
  • Ayse Durnali
  • Saadet Tokluoglu
  • Sema Akinci
  • Kamile Silay
  • Berna Oksuzoglu
  • Necati Alkis
Original Article

Abstract

Skeletal-related events (SREs) for nonsmall cell lung cancer (NSCLC) patients with bone metastasis lead to serious morbidity. The aim of this study was to determine risk factors for SREs in NSCLC patients with bone metastasis and the factors influencing SRE-free survival and overall survival (OS). From 2000 to 2012, we evaluated retrospectively 835 NSCLC patients. Three hundred and thirty-five of them with bone metastasis were included in the study. SREs and the other prognostic factors were evaluated by univariate and multivariate analysis for SRE-free survival and OS. SREs were detected in 244 patients (72.8 %). The most common SREs were the need for radiotherapy (43.2 %) and malignant hypercalcemia (17.6 %). The median time to first SRE was 3.5 months at the median follow-up of 17 months. A multivariate analysis showed that the presence of bone metastasis at diagnosis (p < 0.001), the number of bone metastasis (p = 0.001), baseline hypercalcemia (p = 0.004), and the presence of palliative radiotherapy (p = 0.04) were independent prognostic factors for SRE-free survival. A logistic regression analysis identified that the presence of bone metastasis at diagnosis [odds ratio (OR), 12.6], number of bone metastasis (OR, 3.05), and baseline hypercalcemia (OR, 0.33) were found to be predictive factors in the developing of SRE. The median OS time for patients with SRE was worse than that for patients without SRE (7 vs 12 months, respectively). For OS, male gender, ECOG performance status (PS), high lactate dehydrogenase (LDH) level, hypoalbuminemia, the presence of bone metastasis at diagnosis, the number of bone metastasis, the presence of SREs, the presence of bisphosphonate therapy, and palliative radiotherapy were independent prognostic indicators for OS by the multivariate analysis. Our results indicated that the frequency of SREs was high and the presence of bone metastasis at the time of diagnosis, baseline hypercalcemia, and multiple bone metastases were significant factors predicting the occurrence of SREs. If bone metastases diagnose earlier, treatments for the prevention of SREs may be initiated earlier; thus, the deterioration of quality of life may be preserved.

Keywords

Skeletal-free events SRE-free survival Nonsmall cell lung cancer Bone metastases 

Notes

Acknowledgments

This study was presented in ELCC, 2015, the European Lung Cancer Conference, in a poster session. Ulas A, Bilici A, Durnali A, Tokluoglu S, Akinci S, Silay K, Oksuzoglu B, Alkis N. Risk factors for skeletal-related events in patients with nonsmall cell lung cancer with bone metastases. Ann Oncol, 26, (Suppl 1), 137p.

Conflicts of interest

None

References

  1. 1.
    Brenner H, Francisci S, de Angelis R, et al. Long-term survival expectations of cancer patients in Europe in 2000–2002. Eur J Cancer. 2009;45:1028–41.CrossRefPubMedGoogle Scholar
  2. 2.
    Langer CJ, Besse B, Gualberto A, Brambilla E, Soria JC. The Evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:5311–20.CrossRefPubMedGoogle Scholar
  3. 3.
    Price N. Bisphosphonates to prevent skeletal morbidity in patients with lung cancer with bone metastases. Clin Lung Cancer. 2004;5:267–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Qu X, Huang X, Yan W, Wu L, Dai K. A meta-analysis of FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. Eur J Radiol. 2012;81:1007–15.CrossRefPubMedGoogle Scholar
  5. 5.
    Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655–64.CrossRefPubMedGoogle Scholar
  6. 6.
    Coleman R. Management of bone metastases. Oncologist. 2000;5:463–70.CrossRefPubMedGoogle Scholar
  7. 7.
    Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003;21:3150–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer. 2004;100:2613–21.CrossRefPubMedGoogle Scholar
  9. 9.
    Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366:1527–37.CrossRefPubMedGoogle Scholar
  10. 10.
    Ou SH. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des Devel Ther. 2011;5:471–85.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Delea TE, McKiernan J, Brandman J, et al. Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer. J Thorac Oncol. 2006;1:571–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Hirsh V, Tchekmedyian NS, Rosen LS, et al. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer. 2004;6:170–4.CrossRefPubMedGoogle Scholar
  13. 13.
    Bae HM, Lee SH, Kim TM, Kim DW, Yang SC, Wu HG, et al. Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis. Lung Cancer. 2012;77:572–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Hirsh V, Major PP, Lipton A, et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol. 2008;3:228–36.CrossRefPubMedGoogle Scholar
  15. 15.
    Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005;23:3314–21.CrossRefPubMedGoogle Scholar
  16. 16.
    Rusch VW, Asamura H, Watanabe H, Members of IASLC Staging Committee, et al. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4:568–77.CrossRefPubMedGoogle Scholar
  17. 17.
    Tsuya A, Kurata T, Tamura K, Fukuoka M. Skeletal metastases in non small cell lung cancer: a retrospective study. Lung Cancer. 2007;57:229–32.CrossRefPubMedGoogle Scholar
  18. 18.
    Sekine I, Nokihara H, Yamamoto N, et al. Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy. Lung Cancer. 2009;65:219–22.CrossRefPubMedGoogle Scholar
  19. 19.
    Sun JM, Ahn JS, Lee S, et al. Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases. Lung Cancer. 2011;71:89–93.CrossRefPubMedGoogle Scholar
  20. 20.
    Sathiakumar N, Delzell E, Morrisey MA, et al. Mortality following bone metastasis and skeletal-related events among patients 65 years and above with lung cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999–2006. Lung India. 2013;30:20–6.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Cetin K, Christiansen CF, Jacobsen JB, et al. Bone metastasis, skeletal-related events, and mortality in lung cancer patients: a Danish population-based cohort study. Lung Cancer. 2014;86:247–54.CrossRefPubMedGoogle Scholar
  22. 22.
    Janjan N, Lutz ST, Bedwinek JM, et al. Therapeutic guidelines for the treatment of bone metastasis: a report from the American College of Radiology Appropriateness Criteria Expert Panel on Radiation Oncology. J Palliat Med. 2009;12:417–26.CrossRefPubMedGoogle Scholar
  23. 23.
    Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage nonsmall- cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol. 1991;9:1618–26.CrossRefPubMedGoogle Scholar
  24. 24.
    Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced nonsmall- cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol. 1995;13:1221–30.CrossRefPubMedGoogle Scholar
  25. 25.
    Ferrigno D, Buccheri G. Hematologic counts and clinical correlates in 1201 newly diagnosed lung cancer patients. Monaldi Arch Chest Dis. 2003;59:193–8.PubMedGoogle Scholar
  26. 26.
    Katakami N, Kunikane H, Takeda K, et al. Prospective study on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer-CSP-HOR 13. J Thorac Oncol. 2014;9(2):231–8.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer. 2003;89:877–85.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Danner BC, Didilis VN, Wiemeyer S. Long-term survival is linked to serum LDH and partly to tumour LDH-5 in NSCLC. Anticancer Res. 2010;30:1347–51.PubMedGoogle Scholar
  29. 29.
    Jafri SH, Shi R, Mills G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. BMC Cancer. 2013;13:158–67.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Forrest LM, McMillan DC, McArdle CS. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003;89:1028–30.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Ward KD, Klesges RC. A meta-analysis of the effects of cigarette smoking on bone mineral density. Calcif Tissue Int. 2001;68:259–70.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Trinkaus M, Simmons C, Myers J. Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting. Support Care Cancer. 2010;18:197–203.CrossRefPubMedGoogle Scholar
  33. 33.
    De Marinis F, Eberhardt W, Harper PG. Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel. J Thorac Oncol. 2009;4:1280–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Song Z, Zhang Y. Zoledronic acid treatment in advanced non-small cell lung cancer patients with bone metastases. Med Oncol. 2014;31:898–906.CrossRefPubMedGoogle Scholar
  35. 35.
    Hu X, Zou Q, Jin C. Efficacy of zoledronic acid combined with chemotherapy in treatment of skeletal metastases of non-small cell lung cancer and the bone metabolic markers. Nan Fang Yi Ke Da Xue Xue Bao. 2010;30:1343–6 (Abstract).PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Arife Ulas
    • 1
  • Ahmet Bilici
    • 2
  • Ayse Durnali
    • 3
  • Saadet Tokluoglu
    • 3
  • Sema Akinci
    • 4
  • Kamile Silay
    • 5
  • Berna Oksuzoglu
    • 3
  • Necati Alkis
    • 3
  1. 1.Department of Medical OncologyAnkara Ataturk Training and Research HospitalAnkaraTurkey
  2. 2.Department of Medical Oncology, Medical FacultyIstanbul Medipol UniversityIstanbulTurkey
  3. 3.Department of Medical OncologyAnkara Oncology Teaching and Research HospitalAnkaraTurkey
  4. 4.Department of HematologyAnkara Ataturk Training and Research HospitalAnkaraTurkey
  5. 5.Department of Internal Medicine and Geriatrics, Faculty of Medicine, Ataturk Research and Training HospitalYildirim Beyazit UniversityAnkaraTurkey

Personalised recommendations